References
- IMS Health: “Channel Distribution Dispensed Prescriptions (U.S.), National Sales Perspectives, National Prescription Audit, December 2012.” Available at http://www.imshealth.com/deployedfiles/imshealth/Global/Content/Corporate/Press%20Room/2012_U.S/Channel_Distribution_Dispensed_Prescriptions_U.S.pdf (accessed November 22, 2013).
- Bureau of Labor Statistics (BLS): “Occupational Employment and Wages, May 2012: 29–2052 Pharmacy Technicians.” Available at http://www.bls.gov/oes/current/oes292052.htm (accessed November 20, 2013).
- Bureau of Labor Statistics (BLS): Occupational Employment and Wages, May 2012: 29–1051 Pharmacists. Available at http://www.bls.gov/oes/current/oes291051.htm (accessed November 20, 2013).
- Skibsed, E.T.S, H.F.M, Boelens, J.A., Westerhuis, D.T., Witte, and A.K. Smilde: Simple assessment of homogeneity in pharmaceutical mixing processes using a near-infrared reflectance probe and control charts. J. Pharm. Biomed. Anal. 41(1):26–35 (2006).
- Rutesh, D.H.: Drug Topics: Overview of Pharmaceutical Excipients Used in Tablets and Capsules (2008). Available at http://drugtopics.modernmedicine.com/drug-topics/news/modernmedicine/modern-medicine-news/overview-pharmaceutical-excipients-used-tablets (accessed March 2014).
- Teichman, R.F., L.F. Fallon Jr., and P.W. Brandt-Rauf: Health effects on workers in the pharmaceutical industry: A review. J. Soc. Occup. Med. 38:55–57 (1988).
- Naumann, B.D., and E.V. Sargent: Setting occupational exposure limits for pharmaceuticals. Occup. Med. 12(1):67–80 (1997).
- Heron, R.J., and F.C. Pickering: Health effects of exposure to active pharmaceutical ingredients (APIs). Occup. Med. (Lond) 53:357–362 (2003).
- Zuskin, E., J. Mustajbegovic, E.N. Schachter, et al.: Respiratory findings in pharmaceutical workers. Am. J. Ind. Med. 46:472–479 (2004).
- Tatre, A.: An industrial hygiene monitoring strategy for dust in the pharmaceutical industry. Appl. Occup. Environ. Hyg. 7(11):764–771 (1992).
- Van Nimmen, N.F.J., K.L.C., Poels, and H.A.F. Veulemans: Identification of exposure pathways for opioid narcotic analgesics in pharmaceutical production workers. Ann. Occup. Hyg. 50(7):665–677 (2006).
- Van Nimmen, N.F.J., K.L.C. Poels, M.J. Severi, L. Godderis, and H.A.F. Veulemans: Selecting an appropriate biomonitoring strategy to evaluate dermal exposure to opioid narcotic analgesics in pharmaceutical production workers. Occup. Environ. Med. 67(7):464–470 (2006).
- McDonnell, P.E., J.W. Cherrie, A. Sleeuwenhoek, A. Gilles, and M.A. Coggines: Refinement and validation of an exposure model for the pharmaceutical industry. J. Environ. Monit. 13(3):641–648 (2010).
- Champmartin, C., and F. Clerc: Inhalable dust measurements as a first approach to assessing occupational exposure in the pharmaceutical industry. J. Occup. Environ. Hyg. 11(2):85–92 (2014).
- Boundy, M., D. Leith, and T. Polton: Method to evaluate the dustiness of pharmaceutical powders. Ann. Occup. Hyg. 50(5):453–458 (2006).
- Levin, M., I.K. Koponen, and K.A. Jensen: Exposure assessment of four pharmaceutical powders based on dustiness and evaluation of damaged HEPA filters. J. Occup. Environ. Hyg. 11(3):165–177 (2014).
- AlburtyLab: Investigation into the Impact of Air Pressure Driven Drug Dispensing Machines on the Environment of Pharmacy Workers: Results in 15 U.S. Pharmacies. Publication No. SC-2007–01, 2008. . Available at http://www.scriptpro.com/Safety/Studies/ParataRDS-Study-Comparative-Pharmautomation-Pharmacies/ (accessed August 2013).
- AlburtyLab: Investigation into the Impact of Air Pressure Driven Drug Dispensing Machines on the Environment of Pharmacy Workers: Results in Two U.S. Pharmacies. Publication No. SP-2008–02, 2009. . Available at http://www.scriptpro.com/Safety/Studies/Peer-Review-PEMs-Pharmautomation-Study/ (accessed August 2013).
- National Institute for Occupational Safety and Health (NIOSH): Health Hazard Evaluation Report: Exposures to Pharmaceutical Dust at a Mail Order Pharmacy. DHHS (NIOSH) Pub. No. 2010–0026–3150. Cincinnati, Ohio: NIOSH, 2011.
- National Institute for Occupational Safety and Health (NIOSH): Health Hazard Evaluation Report: Exposures to Pharmaceutical Dust at an Outpatient Pharmacy. DHHS (NIOSH) Pub. No. 2010–0078–3177. Cincinnati, Ohio: NIOSH, 2013.
- National Institute for Occupational Safety and Health (NIOSH): Health Hazard Evaluation Report: Evaluation of Safety Climate, Health Concerns, and Pharmaceutical Dust Exposures at a Mail Order Pharmacy. DHHS (NIOSH) Pub. No. 2012–0044–3199. Cincinnati, Ohio: NIOSH, 2013.
- Fent, K.W., and S. Durgam: Exposures to pharmaceutical dust at a mail order pharmacy. J. Occup. Environ. Hyg. 9: D161–D166 (2012).
- National Institute for Occupational Safety and Health (NIOSH): NIOSH Pocket Guide to Chemical Hazards, M.E. Barsen, ed. DHHS (NIOSH) Pub. No. 2010–168c. Cincinnati, Ohio: NIOSH, 2010.
- American Conference of Governmental Industrial Hygienists (ACGIH®): TLV®s and BEIs Based on the Documentation of the Threshold Limit Values for Chemical Substances and Physical Agents and Biological Exposure Indices. Cincinnati, Ohio: ACGIH, 2013.
- Bristol-Myers Squibb Company: Safety Data Sheet: Lisinopril (2012). Available at http://www.bmsmsds.com/msdsweb/ (accessed August 10, 2013).
- National Institute for Occupational Safety and Health (NIOSH): NIOSH Manual of Analytical Methods, 4th ed., P.C. Schlecht and P.F. O’Connor, eds. . DHHS (NIOSH) Pub. No. 94–113, 1st Supplement Pub. 96–135, 2nd Supplement Pub. 98–119, 3rd Supplement Pub. 2003–154. Cincinnati, Ohio: NIOSH, 2013.
- PubMed Health: “Drugs and Supplements.” Available at http://www.ncbi.nlm.nih.gov/pubmedhealth/s/drugs_and_supplements/a/ (accessed May 8, 2013).
- National Institute for Occupational Safety and Health (NIOSH): NIOSH List of Antineoplastic and Other Hazardous Drugs in Health Care Settings 2012. DHHS (NIOSH) Publication No. 2012–150. Cincinnati, Ohio: NIOSH, 2012.
- Pfizer: Safety Data Sheet: Levothyroxine Sodium Tablets (2011). Available at http://www.pfizer.com/files/products/material_safety_data/PZ01680.pdf (accessed May 8, 2013).
- Bristol-Myers Squibb Company: Safety Data Sheet: Hydrochlorothiazide (2012). Available at http://www.bmsmsds.com/msdsweb/ (accessed May 8, 2013).
- Abbott Labs: Safety Data Sheet: Vicodin ES Tablets (2011). Available at http://www.abbott.com/global/url/content/en_US/20.40:40/general_cont-ent/General_Content_00183.htm (accessed May 8, 2013).
- U.S. Pharmacopeia: USP Reference Standards, Safety Data Sheet: Methotrexate (2013). Available at http://www.usp.org/pdf/EN/referenceStandards/msds/1414003.pdf (accessed May 8, 2013).
- U.S. Pharmacopeia: USP Reference Standards, Safety Data Sheet: Loratadine Related Compound A (2013). Available at http://www.usp.org/pdf/EN/referenceStandards/msds/1370280.pdf (accessed May 8, 2013).
- U.S. Pharmacopeia: USP Reference Standards, Safety Data Sheet: Buspirone Hydrochloride (2006). Available at http://www.usp.org/pdf/EN/referenceStandards/msds/1078802.pdf (accessed May 8, 2013).
- U.S. Pharmacopeia: USP Reference Standards, Safety Data Sheet: Captopril (2013). Available at http://www.usp.org/pdf/EN/referenceStandards/msds/1091200.pdf (accessed May 8, 2013).
- Pfizer: Safety Data Sheet: Gabapentin Tablets (2010). Available at http://www.pfizer.com/files/products/material_safety_data/PZ01158.pdf (accessed May 8, 2013).
- Hoffman-La Roche: Safety Data Sheet: Naproxen Sodium (2006). Available at http://www.roche.com/pages/csds/english/out/0490628.20110225.8049.pdf (accessed May 8, 2013).
- Naumann, B.D.: “Control Banding in the Pharmaceutical Industry,” 2005. Available at http://www.aioh.org.au/downloads/documents/ControlBandingBNaumann.pdf (accessed April 13, 2013).
- Naumann, B.D., E.V. Sargent, B.S. Starkman, W.J. Fraser, G.T. Becker, and G.D. Kirk: Performance-based exposure control limits for pharmaceutical active ingredients. Am. Ind. Hyg. Assoc. J. 57: 33–42 (1996).
- Zalk, D.M., and D.I. Nelson: History and evolution of control banding: A review. J. Occup. Environ. Hyg. 5: 330–346 (2008).
- Bernstein, J.A., D.I. Bernstein, T. Stauder, Z. Lummus, and I.L. Bernstein: A cross-sectional survey of sensitization to Aspergillus oryzae-derived lactase in pharmaceutical workers. J. Allergy Clin. Immunol. 103: 1153–1157 (1999).
- National Institute for Occupational Safety and Health (NIOSH): NIOSH Alert: Preventing Occupational Exposure to Antineoplastic and Other Hazardous Drugs in Health Care Settings. DHHS (NIOSH) Pub. No. 2004–165. Cincinnati, Ohio: NIOSH, 2004.
- Mader, R.M., B. Rizovski, G.G. Steger, A. Wachter, R. Kotz, and H. Rainer: Exposure of oncologic nurses to methotrexate in the treatment of osteosarcoma. Arch. Environ. Health 51: 310–314 (1996).
- Sessink, P.J., N.S. Friemel, R.B. Anzion, and R.P. Bos: Biological and environmental monitoring of occupational exposure of pharmaceutical plant workers to methotrexate. Int. Arch. Occup. Environ. Health 65: 401–403 (1994).
- Sessink, P.J., B.C. Wittenhorst, R.B. Anzion, and R.P. Bos: Exposure of pharmacy technicians to antineoplastic agents: Reevaluation after additional protective measures. Arch. Environ. Health 52: 240–244 (1997).
- Pfizer: Safety Data Sheet: Methotrexate Tablets (2012). Available at http://www.pfizer.com/files/products/material_safety_data/PZ00130.pdf (accessed July 3, 2013).
- Lloyd, M., P. McElhatton, M. Carr, G. Hall, and R. Hughes: Methotrexate in pregnancy. Rheumatology (Oxford) 44(Comment Letter):697; Author Reply:698 (2005).
- Brent, R.L., S. Tanski, and M. Weitzman: A pediatric perspective on the unique vulnerability and resilience of the embryo and the child to environmental toxicants: The importance of rigorous research concerning age and agent. Pediatrics 113(4 Suppl):935–944 (2004).